NeuroPace to Host Investor Day on January 28th in New York City
Rhea-AI Summary
NeuroPace (NPCE), a medical device company specializing in epilepsy treatment, has announced an upcoming Investor Day scheduled for January 28, 2025, in New York City. The event will run from 9:00 a.m. to 12:00 p.m. ET.
The presentation will showcase the company's RNS technology and future strategic plans. Management will discuss recent results and outline market, product, and clinical development strategies for the RNS System. The event will feature presentations from clinical key opinion leaders and include personal testimony from an RNS patient about their experience with the system.
Positive
- None.
Negative
- None.
News Market Reaction – NPCE
On the day this news was published, NPCE gained 1.10%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
MOUNTAIN VIEW, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that the Company will host an Investor Day from 9:00 a.m. – 12:00 p.m. ET on Tuesday, January 28, 2025 in New York City.
The Investor Day will provide an update on NeuroPace’s vision for its unique RNS technology and will highlight the Company’s plans including presentations from management discussing NeuroPace’s recent results, future plans, and market, product and clinical development strategies for the RNS System. The Company will also host guest speakers, including clinical key opinion leaders and an RNS patient who will provide their personal experience with the RNS System and its impact on their epilepsy.
Use the link below to register for the event:
https://lifescievents.com/event/neuropace/
About NeuroPace, Inc.
Based in Mountain View, Calif., NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is the first and only commercially available, brain-responsive platform that delivers personalized, real-time treatment at the seizure source. This platform can drive a better standard of care for patients living with drug-resistant epilepsy and has the potential to offer a more personalized solution and improved outcomes to the large population of patients suffering from other brain disorders.
Investor Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
jfeffer@lifesciadvisors.com
FAQ
When and where is NeuroPace (NPCE) hosting its 2025 Investor Day?
What topics will be covered at NeuroPace's 2025 Investor Day?
Who will be speaking at the NPCE Investor Day 2025?
How can investors register for NeuroPace's 2025 Investor Day?
